As an innovative technique developer, Creative Biolabs now provides high affinity T cell receptors (TCR) targeting specific antigen for immunodeficiency disorder research and clinical trial purposes.
Immunodeficiency, also known as immune deficiency, is a state in which the immune system’s ability to perform resistance to infectious diseases and some forms of cancer is compromised or entirely absent. There are two types of immunodeficiency: the congenital form (or the primary immunodeficiency), caused by genetic defect in the essential genes involved in maturation of the immune response; and the acquired immunodeficiency (or secondary immunodeficiency) caused by extrinsic factors, such as chemotherapy, some forms of cancer, extremes of age and environmental factors or chronic infections such as AIDS. Among all the immune deficiency disease, acquired immunodeficiency syndrome ( AIDS) has raised to rank in the most frightening health problem all around the world, which is a syndrome caused by the HIV virus and is also the last stage of HIV infection where the body can no longer defend itself and may develop various diseases and infections. HIV stands for human immunodeficiency virus, attacking the immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections; As a result, the number of CD4 cells (T cells) in the body is reduced and the patients are more likely to get various infections or infection-related cancers. In addition, the HIV can avoid the attack from host cytotoxic T lymphocytes (CTLs) via varying the peptide antigen itself. According to statistics, the virus has killed more than 39 million people since its first discovery in 1981. What is even worse, there is currently no efficient cure for HIV or AIDS. However, recently, it is demonstrated that introducing genes encoding T-cell receptor (TCR) specific for human immunodeficiency virus into T cells of infected patients represents a means to quantitatively and qualitatively improve immunity to the virus, and TCR-based immunotherapy targeting HIV-1 has entered Phase I clinical trials. Accordingly, in the past decades, through the cooperation with numerous research institutes, Creative Biolabs has developed high-affinity TCR technology platform and a number of TCRs can be isolate or generate to have high binding affinity and the ability to recognize antigenic variants commonly found during HIV infection.. What’s more, the CD8+cytotoxic-T-lymphocyte (CTL) response for containment of human immunodeficiency virus (HIV) infection has been suggested. Based on this, experienced scientists of Creative Biolabs can screen and isolate high-affinity TCRs from phage display TCR library derived from patient’s CTLs, either with or without the introduction of gene engineering, which can directly target HIV associated antigens carrying potential escape mutants. Then, CD8+cytotoxic-T-lymphocytes are transfected with these high-affinity TCRs to obtain higher anti-HIV activity compared with the normal ones.
According to different requirements from our clients, Creative Biolabs can offer a series of mature and feasible strategies to construct engineered T cells for the targeting therapy of immunodeficiency diseases.
Copyright © 2007 - 2019 Creative Biolabs. All Rights Reserved